Primary Peritoneal Cancer

[Maryther-Oropeza-MD]

This article has been medically reviewed by Marither Oropeza, MD — 2022-5-21

Who are the top experts researching treatments for primary peritoneal cancer?

The top experts researching primary peritoneal cancer are: Paul Haluska, Thomas F. Rocereto and Pavel Blecharz.

What are the top concepts researched in studies about primary peritoneal cancer?

The most researched concepts in studies of primary peritoneal cancer are: Fallopian Tube, Epithelial Ovarian, Phase Trial, Tumor Cells, Long Term, Newly Diagnosed, Radiation Therapy and Evaluate Safety.

What are some of the top places that specialize in primary peritoneal cancer?

Recommended institutions that specialize in primary peritoneal cancer:

Nitin D. Joshi, MD 20055 Lake Chabot Rd # 130, Castro Valley, CA 94546 Phone: +15108880657

Bruckner Oncology 2330 Eastchester Rd, The Bronx, NY 10469 Phone: +17187324050

Dr. Andrew Gaya 116 Harley St, London W1G 7JL, United Kingdom Phone: +442073172552

Health Zoshin Clinic Japan, 〒102-0074 Tokyo, Chiyoda City, Kudanminami, 4 Chome−8−21, Yamawaki Bldg., ５F Phone: +81332371777

Primary Peritoneal Cancer

[Maryther-Oropeza-MD]

This article has been medically reviewed by Marither Oropeza, MD — 2022-5-21

#1	Ignace B P Vergote
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, and University Hospital Leuven, Leuven, Belgium; | Department of Gynecology, UZ Leuven - ... Ovarian Cancer | Neoadjuvant Chemotherapy | Weekly Paclitaxel | Maintenance Therapy | Postmenopausal Women

#2	Eric Pujade‐Lauraine
ARCAGY-GINECO, and GINECO, Paris, France; | Groupe ARCAGY-GINECO, Pôle opérations cliniques, Paris, France | ARCAGY Research, and GINECO, Paris, France; | ARCAGY-GINECO ... Ovarian Cancer | Maintenance Olaparib | Phase Iii | Standard Chemotherapy | Pegylated Liposomal Doxorubicin

#3	Amit Manulal Oza
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; | Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1X8, ... Ovarian Cancer | Maintenance Olaparib | Advanced Solid Tumors | Mirvetuximab Soravtansine | Brca Mutation

#4	Aghajanian Aghajanian
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA | ... Ovarian Cancer | Fallopian Tube | Maintenance Olaparib | Brca Mutation | Weekly Paclitaxel

#5	Mark F Brady
NRG Oncology; Clinical Trial Development Division; Biostatistics & Bioinformatics; Roswell Park Comprehensive Cancer Center, Buffalo, NY. | NRG Oncology SDMC, CTD Division, ... Ovarian Cancer | Gynecologic Oncology | Phase Iii Trial | Primary Therapy | Residual Disease

#6	Robert Allen Burger
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA; | University of Pennsylvania Health System, Division of ... Ovarian Cancer | Gynecologic Oncology | Intraperitoneal Cisplatin | Phase Iii Trial | Radical Hysterectomy

#7	Stephen C Rubin
Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA 19111, USA. Electronic address: Stephen.rubin@fccc.edu. | Division of Gynecologic Oncology, Fox Chase ... Ovarian Cancer | Gynecologic Oncology | Radiation Therapy | Fallopian Tube | Emotion Episodes

#8	Jeffrey M Fowler
Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States. | Department of Obstetrics and ... Endometrial Cancer | Gynecologic Oncology | Weekly Paclitaxel | Young Women | Robotic Surgery

#9	Benjamin E Greer
Presented by Benjamin E. Greer, MD, and Wui-Jin Koh, MD, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington. | From National Comprehensive Cancer ... Cervical Cancer | Gynecologic Oncology | Oral Etoposide | Liposomal Doxorubicin | Epithelial Ovarian

#10	Bradley J Monk
HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ 85016, United States of America. Electronic address: bmonk@gog.org. | Division of ... Ovarian Cancer | Gynecologic Oncology | Pegylated Liposomal Doxorubicin | Radical Hysterectomy | Phase Iii

#11	Nicoletta Colombo
Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY (V.M.); European Institute of Oncology IRCCS, University of ... Ovarian Cancer | Maintenance Olaparib | Brca Mutation | Phase Iii | Mirvetuximab Soravtansine

#12	Robert S Mannel
Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OH 73104, United States of America. Electronic address: Robert-mannel@ouhsc.edu. | The ... Gynecologic Oncology | Ovarian Cancer | Fallopian Tube | Intraperitoneal Cisplatin | Antitumor Activity

#13	Michael A Bookman
University of Arizona, Tucson, AZ; | Director, Gynecologic Oncology Therapeutics, Kaiser Permanente Northern California, San Francisco, CA. | GOG and Kaiser Permanente ... Ovarian Cancer | Gynecologic Oncology | Neoadjuvant Chemotherapy | Multiple Cycles | Phase Iii

#14	Jalid Sehouli
Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany | Charité – Medical University of Berlin, Berlin, Germany; | Department of Gynecology, European ... Ovarian Cancer | Maintenance Therapy | Weekly Paclitaxel | Surgical Outcome | Gynecological Oncology

#15	Jonathan A Ledermann
Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, United Kingdom; | Department of Oncology, UCL Hospitals, London, UK | ... Ovarian Cancer | Maintenance Therapy | Parp Inhibitors | Placebo Patients | Fallopian Tube

#16	Michael J Birrer
The University of Alabama at Birmingham, Birmingham, AL; | Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, United States | ... Ovarian Cancer | Mirvetuximab Soravtansine | Gynecologic Oncology | Gene Expression | Avelumab Maintenance

#17	Ursula A Matulonis
Dana-Farber Cancer Institute, Boston, Massachusetts, United States | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA | Department of ... Ovarian Cancer | Fallopian Tube | Mirvetuximab Soravtansine | Parp Inhibitors | Liposomal Doxorubicin

#18	William Patrick McGuire
Virginia Commonwealth University, Richmond | Virginia Commonwealth University, Richmond, VA, USA | VCU Massey Cancer Center, Richmond, VA; | Division of Hematology, Oncology, ... Ovarian Cancer | Gynecologic Oncology | Liposomal Doxorubicin | Erbb2 Amplification | Oral Etoposide

#19	Richard R Barakat
Northwell Health Cancer Institute, 1111 Marcus Avenue, New Hyde Park, NY 11042, USA. Electronic address: rbarakat@northwell.edu. | Northwell Health Cancer Institute, 1111 ... Endometrial Cancer | Fallopian Tube | Tertiary Cytoreduction | Residual Disease | Ovarian Carcinoma

#20	Richard T Penson
Medical Gynecologic Oncology, Massachusetts General Hospital, Boston, MA; | Harvard Medical School, Massachusetts General Hospital, Boston, USA | Massachusetts General ... Ovarian Cancer | Liposomal Doxorubicin | Fallopian Tube | Psychosocial Issues | Gynecologic Oncology

[Maryther-Oropeza-MD]

This article has been medically reviewed by Marither Oropeza, MD — 2022-5-21

Japan Society Of Gynecologic Oncology Guidelines 2015 For The Treatment Of...

.. including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as ...

Ovarian Cancer | Japan Society | Gynecologic Oncology | Fallopian Tube | Guidelines Treatment

Primary Peritoneal Cancer After Bilateral Salpingo-Oophorectomy In Two Patients...

.. of primary peritoneal cancer after BSO in women with Lynch syndrome or HNPCC.

CASES: The first patient was a 44-year-old woman who underwent hysterectomy with BSO for benign disease. She ...

Lynch Syndrome | Primary Peritoneal Cancer | Peritoneal Neoplasms | Bilateral Salpingo | Genetic Testing

A Phase Ii Clinical Trial Of Pegylated Liposomal Doxorubicin And Carboplatin Plus...

.. or primary peritoneal cancer.

METHODS: Patients with platinum-sensitive, recurrent disease received PLD 30 mg/m(2) and carboplatin area under the curve (AUC) 5 on Day 1 plus bevacizumab ...

Fallopian Tube | Primary Peritoneal Cancer | Pegylated Liposomal Doxorubicin | Local Neoplasms | Carboplatin Bevacizumab

Phase Ii Trial Of Bevacizumab In Persistent Or Recurrent Epithelial Ovarian...

.. and primary peritoneal cancer (PPC). We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody.

PATIENTS AND ...

Gynecologic Oncology | Epithelial Ovarian | Primary Peritoneal Cancer | Local Neoplasms | Monoclonal Antibodies

Long-Term Results Of Dose-Dense Paclitaxel And Carboplatin Versus Conventional...

.. or primary peritoneal cancer. We report the long-term follow-up results for survival.

METHODS: This randomised controlled trial was done at 85 centres in Japan. Patients with stage II-IV ...

Epithelial Ovarian | Fallopian Tube | Dense Paclitaxel | Primary Peritoneal Cancer | Conventional Treatment

Serous Ovarian, Fallopian Tube And Primary Peritoneal Cancers: A Common Disease...

.. comparing primary peritoneal cancer, fallopian tube cancer and ovarian cancer of serous histology, in order to achieve a greater understanding of whether or not these disorders should be ...

Fallopian Tube | Peritoneal Cancer | Serous Ovarian | Poorer Survival | Patients Differences

Dose-Dense Paclitaxel And Carboplatin Vs. Conventional Paclitaxel And Carboplatin...

.. or primary peritoneal cancer was conducted. These patients underwent NAC followed by interval debulking surgery at the Hyogo Cancer Center (Hyogo, Japan) between January 2006 and December ...

Fallopian Tube | Neoadjuvant Chemotherapy | Primary Peritoneal Cancer | Dense Paclitaxel | Peritoneal Neoplasms

Clinical Activity Of Gemcitabine Plus Pertuzumab In Platinum-Resistant Ovarian...

.. or primary peritoneal cancer who had received a maximum of one prior treatment for recurrent cancer were randomly assigned to gemcitabine plus either pertuzumab or placebo. Collection of

Pertuzumab Gemcitabine | Clinical Activity | Monoclonal Antibodies | Fallopian Tube | Resistant Ovarian

Statement By The Kommission Ovar Of The Ago: The New Figo And Who Classifications...

.. and primary peritoneal cancers. The new classification has become effective with its publication at the beginning of 2014. Following recent findings on the pathogenesis of ovarian, ...

Fallopian Tube | New Figo | Primary Peritoneal Cancer | Grade Serous | Brenner Tumors

Safety And Activity Of Mirvetuximab Soravtansine (Imgn853), A Folate Receptor...

.. or primary peritoneal cancer received IMGN853 at 6.0 mg/kg (adjusted ideal body weight) once every 3 weeks. Eligibility included a minimum requirement of FRα positivity by ...

Mirvetuximab Soravtansine | Folate Receptor | Drug Conjugate | Resistant Ovarian | Fallopian Tube

Serous Ovarian, Fallopian Tube And Primary Peritoneal Cancers: A Comparative...

.. and primary peritoneal cancers. A comparison of risk factors for these tumor types may shed light on common or distinct aetiological pathways involved in these types of cancer. We ...

Fallopian Tube | Peritoneal Cancer | Serous Ovarian | Odds Ratios

Improved Optimal Cytoreduction Rates For Stages Iiic And Iv Epithelial Ovarian,...

OBJECTIVE: To determine the impact of the incorporation of extensive upper abdominal debulking procedures on the rates of optimal primary cytoreduction and complications in stages IIIC and IV ...

Fallopian Tube | Optimal Cytoreduction | Stages Iiic | Primary Peritoneal | Operative Time

A Phase Ii Evaluation Of The Potent, Highly Selective Parp Inhibitor Veliparib In...

BACKGROUND: Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2. We studied the clinical activity and toxicity of ...

Germline Brca1 | Brca2 Mutation | Parp Inhibitor Veliparib | Epithelial Ovarian | Local Neoplasms

Safety And Efficacy Of Patupilone In Patients With Advanced Ovarian, Primary...

PURPOSE To evaluate the safety, maximum tolerated dose (MTD), and pharmacokinetics of patupilone administered once every 3 weeks with proactive standardized diarrhea management in patients ...

Patupilone Patients | Peritoneal Cancer | Advanced Ovarian | 3 Weeks | Primary Fallopian

A Phase Ii Evaluation Of Nanoparticle, Albumin-Bound (Nab) Paclitaxel In The...

BACKGROUND: Nab-paclitaxel is a novel Cremophor®-free nanoparticle of albumin-stabilized paclitaxel, which has favorable efficacy and toxicity characteristics relative to other solvent-based ...

Gynecologic Oncology | Peritoneal Cancer | Resistant Ovarian | Fallopian Tube | Neoplasms Paclitaxel

Phase Ii Study Of Bevacizumab And Pemetrexed For Recurrent Or Persistent...

OBJECTIVE: We aimed to evaluate the efficacy and safety of combination bevacizumab/pemetrexed for the treatment of recurrent epithelial ovarian cancer (EOC).

METHODS: Platinum-sensitive or ...

Epithelial Ovarian | Fallopian Tube | Primary Peritoneal Cancer | Bevacizumab Carcinoma | Aged Neoplasm

Primary Peritoneal Cancer In Lynch Syndrome

.. of primary peritoneal cancer after adnexectomy remains unknown. We here report a case of primary peritoneal cancer in a woman affected by Lynch syndrome who underwent ...

Lynch Syndrome | Primary Peritoneal | Endometrial Cancer | Germline Mutation | Publication Colorectal Neoplasms

A Phase Ii Trial Of Paclitaxel Poliglumex In Recurrent Or Persistent Ovarian Or...

.. or primary peritoneal cancer (EOC) in second or third line treatment.

METHOD: Twenty-five patients received PPX at 235 mg/m(2) every 21 days (Cohort 1). At a planned analysis following ...

Paclitaxel Poliglumex | Peritoneal Cancer | Antineoplastic Agents | Ovarian Neoplasms | Fallopian Tube

Usefulness Of Third-Line Chemotherapy For Women With Recurrent Ovarian, Fallopian...

.. and primary peritoneal cancer treated with platinum-taxane regimens as first-line therapy.Patients and methodsWe retrospectively reviewed the medical records of women with ovarian, ...

Recurrent Ovarian | Fallopian Tube | Thirdline Chemotherapy | Primary Peritoneal Cancer | Firstline Therapy

Treatment Of Recurrent Or Persistent Platinum-Refractory Ovarian, Fallopian Tube...

OBJECTIVE: To determine the nature and degree of toxicity, response rate, quality of life (QOL), and progression-free interval in women with platinum-resistant refractory ovarian or peritoneal ...

Gemcitabine Topotecan | Peritoneal Cancer | Quality Life | Ovarian Neoplasms | Aged Neoplasm